CG Results is delighted to announce that it has advised E2X.COM LTD (“E2X.COM”) on its acquisition by Apply Digital, a portfolio company of Los Angeles-based Interlock Equity.

E2X.COM is an award-winning, specialist commerce strategy and development agency, providing composable commerce, content and operations services to enterprises and other high growth companies. Founded four years ago, E2X.COM focused on pivoting clients to a modern technology stack, moving away from older ‘monolithic’ on premise technology to ‘MACH’ philosophy and technologies, (Microservices, API-first, Cloud Native and Headless) and was one of the founding members of the MACH Alliance.

E2X.COM strengthens Apply Digital’s coverage in Europe and furthers its expertise across MACH technologies, focusing on composable products, digital experience and now commerce. The strategic partnership will form one of the largest MACH-focussed, digital solutions companies across the areas of commerce and digital experiences.

This transaction is the first of note in Europe in the MACH alliance. It is the 3rd commerce services transaction completed by CG Results and the second deal since CG Results joined forces with Canaccord Genuity, one of the leading global M&A advisers to commerce services, in August 2022.

CG Results is delighted to announce that it has advised CSIS Security Group A/S (“CSIS”) on its acquisition by Allurity AB, a portfolio company of Trill Impact, the pioneering Impact House.

Founded in 2003, CSIS is a leading provider of advanced cybersecurity capabilities, focused on actionable and intelligence-driven detection and response services, addressing the most complex cyber challenges. Central to CSIS’ unique positioning is its proprietary technology, scalable services, actionable threat intelligence and world-class team of security professionals. From its base in Denmark, the company supports some of the most recognised brands in multiple industries throughout the Nordics, the UK, and the US.

CSIS strengthens Allurity’s coverage in Northern Europe and furthers its ambition of becoming Europe’s preferred cybersecurity provider. Allurity’s acquisition will also accelerate and strengthen CSIS’ strategy execution across its key lines of business: Managed Detection & Response, Cyber Threat Intelligence, Brand Protection, Emergency Response and Consultancy Services.

This transaction is the 13th cybersecurity transaction completed by CG Results in Europe and the first since CG Results joined forces with Canaccord Genuity in August. The transaction cements our position as the most active advisor in the cyber security space in Europe with unrivalled expertise and global reach.

>>>>> Read the press release here

CG Results Healthcare is pleased to announce that it has advised Noramco, a leading speciality API developer and manufacturer, on the divestment of its API manufacturing site in Coventry, Rhode Island, to Pharmaron.

The Coventry site has an established history of cGMP small molecule API manufacturing from pilot kilogram to commercial metric ton scales and its state-of-the-art manufacturing facilities have been inspected and approved by the FDA, EMA and other regulatory authorities.

Pharmaron acquired the facility to expand its chemistry and manufacturing services into the USA, an important step in establishing its global platform. Existing capabilities at Coventry add to Pharmaron’s array of services, strengthening its ability to offer partners customised chemistry and manufacturing solutions around the world.

This cross-border transaction is CG Results Healthcare’s fourth successful manufacturing asset divestment this year, underlining our industry leadership in this space and ability to complete transactions globally.

We are delighted to announce that CG Results has advised Growth Capital Partners (“GCP”) on its minority investment in Container Solutions (“CS”), a specialist cloud services provider that solves business problems by designing, building and implementing technology solutions in a Cloud Native manner.

This transaction demonstrates CG Results’ leading position in the technology services sector, and further highlights our strong pure-play cloud services expertise having previously advised RedPixie on its acquisition by Hewlett Packard Enterprise and OCSL on its disposal to Cancom.

Founded in 2014 by Jamie Dobson and Pini Reznik in Amsterdam, CS has built a workforce of over 100 people with operations across the globe and key hubs in London, Amsterdam, Montreal and Berlin. The business has delivered rapid year on year growth by winning and growing an attractive base of large clients who want to modernise their approach to cloud technology.

GCP’s investment will support Container Solutions’ ambitious growth plans, supporting existing clients whilst winning new strategic relationships, all underpinned by the business’ specialist and highly sought-after technical capabilities.

>>>> Read the press release here

The board of directors (the “Board”) of Sino Biopharmaceutical Limited (the “Company”, together with its subsidiaries, the “Group”) announces that on May 18, 2022, Chia Tai‑Tianqing Pharmaceutical Group Co., Ltd (“CTTQ”), a subsidiary of the Company, has entered into a definitive agreement with Symphogen A/S (“Symphogen”), acquiring the Sym022 programme, an anti-LAG3 monoclonal antibody (the “Product”). Symphogen is a wholly-owned subsidiary of Servier, a global independent pharmaceutical company, and is Servier’s Antibody Center of Excellence.

The Product is a recombinant, fully human effector-function attenuated anti-LAG-3 monoclonal antibody which has shown significant tumour growth inhibition potential in the pre-clinical stage. The Product has completed two phase 1 clinical trials and the results show it is safe and well-tolerated both as a monotherapy and in combination with other checkpoint inhibitors.

The transaction is subject to closing conditions and is expected to complete in June 2022. The sale of the Product was managed by CG Results Healthcare.

CG Results is pleased to announce that it has advised Search Laboratory, an award-winning integrated digital agency, on its acquisition by Havas Group. Search Laboratory is dedicated to searching for the truth in data, with offices in Leeds, London, Austin and New York.

This deal further cements CG Results’ position as a leading advisor in the digital marketing services and marketing software sectors.

Search Laboratory will be integrated into Havas Media Group as a core part of its offering alongside Havas Media, Havas Entertainment and Havas Market. The acquisition further strengthens the media group’s digital marketing and data capabilities both within the UK and internationally, as well as enabling it to tap into a new talent pool outside of its existing offices in London and Manchester.

Founded in 2005, Search Laboratory is one of only a handful of Google Marketing Platform Sales Partners trusted to offer expert implementation, training and ongoing support for the platform’s advanced suite of tools. Its 150 experts deliver profitable, data-driven digital marketing campaigns across 35 countries to some of the world’s leading brands, such as Mars, UiPath, Appian and Burton Snowboards. Over the years the agency has won multiple industry awards and been featured in the Sunday Times Top 100 Best Companies to Work list eight times.

Chris Attewell, CEO of Search Laboratory, says: “We feel like we have found a natural new home with Havas Media Group. Our visions and ethos are very much aligned, and service offerings complement each other well. This is the next phase in our growth story, and we can’t wait to work together and open up mutual opportunities for our staff and clients alike.”

Yannick Bolloré, Chairman and CEO of Havas Group, adds: “The acquisition of Search Laboratory comes at a time where Havas Media Group is experiencing an impressive period of growth and momentum. Continuing to invest in HMG is part of a global transformation plan to deliver more data led media experiences for both local and global clients. Search Laboratory’s sophisticated expertise in data and analytics perfectly complements our own to create an enhanced offering that will help brands to activate their data in more meaningful ways. I wish Chris Attewell and the teams a very warm welcome to our Group.”

Patrick Affleck, CEO, Havas Media Group UK & Ireland, comments: “We are thrilled that Search Laboratory will be joining Havas Media Group, further boosting our digital and data capabilities for our clients. They are market leaders in data driven digital and performance marketing, and as the industry prepares for a new, cookieless future, their advanced data and analytics services will enable our clients to better activate and extract strategic value from their first party data. With a highly experienced senior team and a diverse client base spanning several verticals, Search Laboratory represents an exciting growth opportunity for Havas Media Group in the UK and internationally.”

Search Laboratory’s current management team, led by CEO Chris Attewell and Founder and Executive Chairman Ian Harris, will continue to lead the agency.


Novartis has divested its Ringaskiddy campus to Sterling Pharma Solutions, a global contract development and manufacturing organisation, backed by Global Healthcare Opportunities (GHO Capital Partners LLP), the European specialist investor in global healthcare. The site currently manufactures a number of APIs across a range of therapeutic areas, and the deal includes an ongoing supply agreement between Sterling and Novartis from the Ringaskiddy facility.

The 111-acre facility, which includes three active pharmaceutical ingredient (API) manufacturing buildings, as well as facilities to support development and scale-up, complements Sterling’s core business focus and expands its global API manufacturing capabilities. The sale is expected to close in Q4 2022. Upon closing, the workforce will transition to Sterling.

This deal represents CG Results’ 6th deal advising Novartis over the past 2 years.

We are delighted to announce that CG Results has advised Livingbridge on its investment in Quorum Cyber, a leading UK-based cyber security services business delivering managed detect and response capabilities to teams and organisations globally.

This transaction is the 10th cyber security transaction completed by CG Results in Europe and cements our position as the leading advisor in the sector. Other recent transactions include advising Outpost24 on its acquisition of Blueliv, Tenzing on its investment in MetaCompliance and Boldon James on its acquisition by Help Systems. The transaction also highlights CG Results’ strong relationships with the mid-cap private equity community.

Founded in 2016 by CEO Federico Charosky, Quorum Cyber’s innovative services enable enterprises including banks, cloud providers and major brands to thrive in an increasingly hostile digital landscape.

Livingbridge’s investment includes growth capital to enable Quorum Cyber to capitalise on strong macro tailwinds and execute its ambitious growth plans through increased investment in its solutions as well as sales and marketing functions.

We are delighted to announce that CG Results has advised Horizon Capital on its investment in BP3 Global, a European and North American provider of intelligent automation services and solutions.

This transaction further cements CG Results’ position as the leading advisor in the intelligent automation sector, having previously advised Roboyo on its investment from MML Capital and Symphony Ventures on its acquisition by SYKES Enterprises.

BP3 has over 130 employees globally and plans further growth in the intelligent automation market with a particular focus on intelligent document processing, robotic process automation, and intelligent process automation. BP3 also plans to expand into new markets to provide clients around the world with a ‘more focus, more foresight, more follow-up approach’ to every engagement.

The investment in BP3 Global commences Horizon Capital’s buy and build in the intelligent automation market, committing £25m to their latest strategy. The new investment will accelerate BP3’s organic growth and includes significant follow-on funding to support the company’s ambition to complete multiple acquisitions in the growing and fragmented market.